Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)

NCT06533553 is registered in ClinicalTrials.gov with Areteia Therapeutics as lead sponsor.

NCT NCT06533553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Areteia Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 9, 2024
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease